Butenafine HCI data

Investigators reported at the American Academy of Dermatology meeting that DERM's antifungal agent showed mycological cure rates of 90 percent and 88 percent after four weeks of once-daily treatment in two studies.

A total of 269 patients were evaluated in two multi-center, vehicle-controlled, randomized, double-blind Phase III trials. Patients received either 1 percent butenafine cream or vehicle cream, and were evaluated three times over four weeks of therapy, and at four weeks following therapy. ...